Jagsonpal Pharmaceuticals Ltd

ESOP allotment details

• 1,01,825 equity shares allotted under JPL ESOP 2022 to eligible employees on vesting.
• Shares rank pari-passu with existing equity shares.
• Date of issue: 30 September 2026.
• Total issued shares after this issue: 6,60,59,245.
• Total issued share capital after this issue: Rs. 13,21,18,490.
• Distinctive numbers for new shares: 6,75,57,421 to 6,76,59,245.
• ISIN: INE048B01035.
• Exercise price per share: Rs 94 for 100,000 shares; Rs 115.60 for 1,825 shares.
• Premium per share: Rs 92 for 100,000 shares; Rs 113.60 for 1,825 shares.

Jagsonpal Pharmaceuticals Limited — Closure of Trading Window from Thursday, October 01, 2026; will open 48 (Forty Eight) hours after declaration of unaudited financial results (Standalone & Consolidated) for the quarter and six months ended on September 30, 2026.

Acquisition overview

• Acquisition via slump sale on a going-concern basis per the BTA.
• Initial consideration of ₹23.7 crores on closing.
• Additional ₹23.0 crores contingent on FY2027-28 sales; cap ₹46.7 crores.
• Completion expected on or before 01 November 2026, subject to conditions precedent.
• FY2025-26 turnover of Wellness Portfolio was ₹24.6 crores.
• Acquisition to strengthen portfolio and expand women's health presence.
• Portfolio to be integrated with Jagsonpal's existing platform and distribution network.
• Not a related party transaction; promoter group has no interest.

Acquisition details

• Target: Wellness Portfolio of Group Pharmaceuticals Limited, Indian pharmaceutical business.
• Portfolio turnover FY2025-26: ₹24.6 crores.
• Not a related party; no promoter/group interest.
• Industry: Pharmaceutical; presence in India.
• Purpose: strengthen portfolio, expand women's health, broaden market reach.
• Regulatory approvals: none required.
• Timeline: completion on/before 01 November 2026, subject to conditions.
• Consideration: ₹23.7 crore on closing; up to ₹23.0 crore later; cap ₹46.7 crore.
• Shareholding acquired: not disclosed.
• Background: Group Pharma Wellness Portfolio comprises products, assets, contracts, employees; presence in India.

AGM Details

• AGM held on 18 September 2026 at 3:30 PM via VC/OAVM.
• Record date: 11 September 2026.
• Total shareholders on record: 26,852.
• Attendance via VC: 5 promoters and 84 public.
• Total resolutions passed: 5.

Key Resolutions

• Item 1 (Ordinary): Adoption of Audited Financial Statements for the year ended 31 March 2026.
• Item 2 (Ordinary): Declaration of Dividend for the year ended 31 March 2026.
• Item 3 (Ordinary): Reappointment of Prithipal Singh Kochhar by rotation.
• Item 4 (Ordinary): Ratification of remuneration payable to M/s Kirit Mehta & Co. LLP for 2027.
• Item 5 (Special): Appointment of Anil Kumar Matai as Independent Director.

Voting Results

• Item 1 approved with requisite majority (99.99% in favour).
• Item 2 approved with 99.99% in favour.
• Item 3 approved with 99.99% in favour.
• Item 4 approved with 99.98% in favour.
• Item 5 approved with 99.99% in favour.

Director Changes

• Prithipal Singh Kochhar reappointed by rotation.
• Anil Kumar Matai appointed as Independent Director.

Auditors & Fees

• Remuneration for Cost Auditors ratified for FY2027.

AGM Details

• Date, time, mode: 18 Sep 2026, 3:30 p.m. IST, via VC/OAVM.

Chairmanship

• Chairperson elected: Manish Gupta due to absence of Harsha Raghavan.

Key Resolutions Put to Vote

• Adoption of Audited Financial Statements for FY2026 (Ordinary).
• Dividend declaration for FY2026 (Ordinary).
• Reappointment of Kochar by rotation (Ordinary).
• Ratification of remuneration to Cost Auditors for FY2027 (Ordinary).
• Appointment of Anil Kumar Matai as Independent Director (Special).

Voting & Results Status

• Results to be announced with Scrutinizer's Report within 2 working days.

Director Changes & Appointments

• Kochar retires by rotation; eligible for reappointment.
• Anil Kumar Matai appointed as Independent Director (proposed).

Auditors & Remuneration

• Cost Auditors remuneration ratified for FY2027.

Other Material Approvals

• Scrutinizer appointed; results disseminated to exchanges and on company site.